| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Pivotal Phase 3 RCTs have now published: SYNCHRONIZE-1 (obesity, 76 weeks) in The New England Journal of Medicine and SYNCHRONIZE-MASLD in Nature Medicine, alongside the earlier Phase 2 program. This lifts the compound off the Phase 2 ceiling toward the multiple-RCT tier. Held at 22 rather than the maximum because the broader Phase 3 program (SYNCHRONIZE-2, LIVERAGE, SYNCHRONIZE-CVOT) is still ongoing and no regulatory submission has been filed. |
22 / 25 |
| Sample Size | SYNCHRONIZE-1 randomized 725 adults across 118 sites in 14 countries over 76 weeks, adding a well-powered Phase 3 cohort on top of the Phase 2 obesity and MASH trials. Cumulative reported human evidence now exceeds 1,000 participants, though it remains well below the multi-thousand pivotal programs of cagrilintide and retatrutide. |
10 / 20 |
| Replication | Survodutide now shows consistent effects across multiple Boehringer Ingelheim Phase 3 trials in distinct populations (obesity in SYNCHRONIZE-1, steatotic liver disease in SYNCHRONIZE-MASLD), a meaningful step up from the single-trial Phase 2 base. Held below the top of the band because all trials share a single sponsor and no independent academic replication yet exists. |
8 / 20 |
| Journal Impact Factor | Primary Phase 3 results are now published in The New England Journal of Medicine (SYNCHRONIZE-1) and Nature Medicine (SYNCHRONIZE-MASLD), both top-tier journals (IF 8+), up from the earlier eClinicalMedicine placement of the Phase 2 data. |
15 / 15 |
| Funding Independence | All trials, Phase 2 and Phase 3, are funded by Boehringer Ingelheim in collaboration with Zealand Pharma. Rigorously conducted and pre-registered, but entirely industry funded with no independent replication. |
3 / 10 |
| Population Diversity | SYNCHRONIZE-1 enrolled across 14 countries spanning North America, Europe, and East Asia (roughly 47% North American, 21% European, 20% East Asian), with about 59% female participants, a more geographically and sex-diverse cohort than the Western-weighted Phase 2. |
4 / 5 |
| Researcher h-Index | Lead investigators are senior endocrinology and hepatology researchers from Boehringer Ingelheim and academic collaborating sites, with h-Indexes above 20. |
5 / 5 |